Study Purpose: This study is testing a new medicine called telitacicept to see if it helps people with generalized myasthenia gravis (MG). MG is a condition where the muscles get weak because the immune system attacks the connection between nerves and muscles. This medicine works by stopping certain signals in the immune system that might be causing the muscle weakness.

Study Details: The study is a type of research known as a "randomized, double-blind, placebo-controlled" study. This means some participants will get telitacicept, and others will get a placebo (a pill with no medicine). Neither the doctors nor the participants will know who gets which. It includes an open-label extension, where everyone gets the real medicine later on.

• **Duration:** Participation involves several visits over an extended period, exact length varies.
• **Eligibility:** You must be 18 or older, diagnosed with MG, and meet specific health criteria.
• **Risks:** There are potential risks, including side effects; discuss with your doctor.